Jun 30, 2026 7:00am EDT Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Jun 16, 2026 7:00am EDT Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial